China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai’s gabapentin in the United States.
Gabapentin: Approved for Treatment of Neuropathic Pain and Epilepsy
Yongtai’s gabapentin received approval in the US in August 2020 for the treatment of adult patients with postherpetic neuralgia and as an adjuvant treatment for partial seizure epilepsy in patients aged three and above. This antiepileptic drug’s approval expands the treatment options available to patients in the US, addressing significant unmet medical needs.
Hepalink’s Global Presence and Marketing Expertise
Hepalink boasts a comprehensive self-operated team, market insight system, and marketing support system across seven countries worldwide, including the United States, United Kingdom, Germany, Italy, Poland, and Spain. With a mature self-operated sales network and channels, Hepalink is well-positioned to effectively market and commercialize gabapentin in the US, leveraging its extensive experience and reach in the pharmaceutical industry.-Fineline Info & Tech
